Referencia número: HY-10587

BIX-01294

27 Cited Publications

Revisión del cliente

Based on 27 publication(s) in Google Scholar

BIX-01294 is a reversible and highly selective G9a and GLP Histone Methyltransferase inhibitor, with IC₅₀s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy. BIX-01294 has antitumor activity in recurrent tumor cells.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 98.44%
No. CAS: 935693-62-2
Fòrmula: C₂₈H₃₈N₆O₂
Peso molecular:490.64

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

BIX-01294 Chemical Structure

No. CAS: 935693-62-2

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (27)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target^[2]

EHMT2/G9a/KMT1C

EHMT1/GLP/KMT1D

Ver todos los productos específicos de isoformas Histone Methyltransferase :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	2.8 μM Compound: BIX01294	Antiproliferative activity against human A549 cells after 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK8 assay	[PMID: 27393948]
HEK293	IC₅₀	2.05 μM Compound: 38; BIX01294	Cytotoxicity against HEK293 cells Cytotoxicity against HEK293 cells	[PMID: 34107385]
HEK293	IC₅₀	2.05 μM Compound: BIXO1294	Cytotoxicity HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs Cytotoxicity HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs	[PMID: 38056296]
HeLa	IC₅₀	0.966 μM Compound: BIX-01294	Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay	[PMID: 29624387]
HepG2	IC₅₀	3.7 μM Compound: BIX01294	Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay	[PMID: 27393948]
HepG2	IC₅₀	4800 nM Compound: BIX01294; 1	Cytotoxicity against human HepG2 cells after 3 days by CellTiter blue assay Cytotoxicity against human HepG2 cells after 3 days by CellTiter blue assay	[PMID: 29308121]
HFF	IC₅₀	4997 nM Compound: 18; BIX01294	Cytotoxicity against HFF Cytotoxicity against HFF	[PMID: 30366254]
HL-60	IC₅₀	2.2 μM Compound: BIX01294	Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay	[PMID: 27393948]
K562	IC₅₀	3.9 μM Compound: BIX01294	Antiproliferative activity against human K562 cells after 48 hrs by CCK8 assay Antiproliferative activity against human K562 cells after 48 hrs by CCK8 assay	[PMID: 27393948]
L02	IC₅₀	4.28 μM Compound: BIX-01294	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 2 days by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 2 days by MTT assay	[PMID: 37788550]
MCF7	EC₅₀	3.3 μM Compound: 1; BIX01294	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31627059]
MDA-MB-231	EC₅₀	2.9 μM Compound: 1; BIX01294	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 31627059]
MDA-MB-231	EC₅₀	2700 nM Compound: 2	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 38799223]
MDA-MB-231	IC₅₀	500 nM Compound: 2	Downregulation of H3K9me2 level in human MDA-MB-231 cells measured after 48 hrs by Western blot analysis Downregulation of H3K9me2 level in human MDA-MB-231 cells measured after 48 hrs by Western blot analysis	[PMID: 38799223]
MDA-MB-231	IC₅₀	500 nM Compound: 37; BIX01294	Reduction in H3K9me2 level in human MDA-MB-231 cells incubated for 48 hrs by ChIP assay Reduction in H3K9me2 level in human MDA-MB-231 cells incubated for 48 hrs by ChIP assay	[PMID: 36528996]
MDA-MB-231	IC₅₀	9.6 μM Compound: 133; BIX-01294	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 35531606]
Vero C1008	IC₅₀	1 μM Compound: BIX-01294	Antiviral activity against Ebolavirus Mayinga infected in African green monkey Vero E6 cells after 72 hrs by eGFP assay Antiviral activity against Ebolavirus Mayinga infected in African green monkey Vero E6 cells after 72 hrs by eGFP assay	[PMID: 29624387]

In Vitro

BIX-01294 (2 μM; 48 h) selectively inhibits recurrent tumor cell growth^[1].
BIX-01294 (1 μM) leads to a marked increase in phosphorylation of S345 of MLKL^[1].
BIX-01294 (1 μM) significantly upregulates the canonical p53 targets Cdkn1a (p21) and Gadd45a in recurrent tumor cell lines^[1].
BIX-01294 (1 μM; 6 days) causes the reduction in H3K9me2 levels in primary and recurrent tumor cells^[1].
BIX-01294 leads to necroptotic cell death in recurrent tumor cells. Necrostatin-1 (30 μM) partially reverses cell death induced by BIX-01294 (750 nM; 24 h)^[1].
BIX-01294 (4.1 μM; for 2 days) causes around a 20% reduction, concomitant with a comparable increase in the unmodified H3K9 fragment in H3K9me2 in mouse ES cells. BIX-01294 causes pronounced reduction in H3K9me2 and a small decrease for H3K9me3 and H3K9me1 in wild-type ES cells^[2].
BIX-01294 has no inhibition of the other histone methyltransferases even at concentrations of 45 μM. BIX-01294 does not affect SUV39H1 (H320R) and PRMT1 within the tested concentration range (up to 10 μM)^[2].
BIX-01294 inhibits G9a in an uncompetitive manner with S-adenosyl-methionine (SAM)^[2].
BIX-01294 (1 μg/mL) causes reduction in the BrdU incorporation of fetal PASMCs. BIX-01294 treatment decreases the PASMCs migration induced by PDGF^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Primary or recurrent tumor cells
Concentration:

2 μM
Incubation Time:

48 hours
Result:

Selectively inhibited recurrent tumor cell growth.

In Vivo

BIX-01294 (10 mg/kg; IP; three times a week for 2 weeks) significantly reduces tumor growth and tumor burden in recurrent tumor cells. Primary tumor growth is not inhibited^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female MMTV-rtTA;TetO-Her2/neu (MTB;TAN) and TetO-Her2/neu (TAN) mice with recurrent or primary tumor cells^[1]
Dosage:

10 mg/kg
Administration:

IP; three times a week for 2 weeks
Result:

Significantly reduced tumor growth and tumor burden in recurrent tumor cells.
Primary tumor growth was not inhibited.
Slowed the growth of orthotopic recurrent tumors in athymic nude recipients.

Chemical Information

No. CAS 935693-62-2
Appearance Solid
Peso molecular 490.64
Fòrmula C₂₈H₃₈N₆O₂
Color White to off-white
SMILES

COC1=C(OC)C=C(C(NC2CCN(CC3=CC=CC=C3)CC2)=NC(N4CCN(C)CCC4)=N5)C5=C1
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (27)

All Bio/Physico-chemical AssayELISACell Proliferation/Viability AssayWBRT-PCR

Sort by:

Journal Impact Factor

Nat Microbiol

A host-directed adjuvant sensitizes intracellular bacterial persisters to antibiotics. [Abstract]

2025 Oct 10. PMID: 41073665

BIX-01294 purchased from MedChemExpress. Usage Cited in: Nat Microbiol. 2025 Oct 10. [Abstract]

Both KL1 (40, 100 µM) and BIX-01294 (1, 4 µM) reduced ROS levels at 4 hpi. Chemiluminescent L-012 probes were used to quantify reactive species.

BIX-01294 purchased from MedChemExpress. Usage Cited in: Nat Microbiol. 2025 Oct 10. [Abstract]

Inhibition of EHMT2/G9a phenocopied KL1-mediated sensitization in intracellular S. aureus. A selective EHMT2/G9a inhibitor, BIX-01294 (BIX; 1–10 µM), increased the bioluminescence signal (grey bars) of strain JE2-lux compared to the vehicle control (Veh; 0.1% DMSO). Cytotoxicity of BIX was also assessed (red circles). Representative data of 3 experiments (n = 6, two-sided unpaired t-test) were obtained.
ACS Nano

Binary Colloidal Crystals Promote Cardiac Differentiation of Human Pluripotent Stem Cells via Nuclear Accumulation of SETDB1. [Abstract]

2023 Feb 14;17(3):3181-3193. PMID: 36655945
J Exp Clin Cancer Res

IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE2. [Abstract]

2018 Aug 17;37(1):196. PMID: 30119635

BIX-01294 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Aug 17;37(1):196. [Abstract]

The relative mRNA levels of Ki67 and PCNA in primary CRC cells responding to rhIL-33 (100 ng/mL) incubation and/ or indicated inhibitors (SB203580, 10 μg/mL; PD98059, 20 μg/mL; SP600125, 10 μg/mL; BIX01294, 2 μM; 5Aza, 10 μM; SC560, 0.1 μg/mL; celecoxib, 20 μg/mL) for 24 h.
Adv Sci (Weinh)

KDM3A Ablation Activates Endogenous Retrovirus Expression to Stimulate Antitumor Immunity in Gastric Cancer. [Abstract]

2024 Jul 19:e2309983. PMID: 39031630
Cell Death Dis

Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells. [Abstract]

2019 Apr 15;10(5):331. PMID: 30988278
Cell Death Dis

G9A promotes tumor cell growth and invasion by silencing CASP1 in non-small-cell lung cancer cells. [Abstract]

2017 Apr 6;8(4):e2726. PMID: 28383547

BIX-01294 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2017 Apr 6;8(4):e2726. [Abstract]

Upper and middle panels: WB detection of H3K9me2 and G9A in PC9 and A549 cells treated with 0, 1, 2.5, 5 or 10 μM BIX-01294. The total level of histone H3 and actin serve as loading controls. Lower panel: WB detection of the total (T-) level of and phosphorylated (P-) ERK kinase in PC9 and A549 cells treated with 0, 1, 5 or 10 μM BIX-01294. GAPDH serves as the loading control
Cell Syst

A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]

2018 Apr 25;6(4):424-443.e7. PMID: 29655704
NPJ Regen Med

Epigenetic mechanisms regulate sex differences in cardiac reparative functions of bone marrow progenitor cells. [Abstract]

2024 Apr 29;9(1):17. PMID: 38684697

BIX-01294 purchased from MedChemExpress. Usage Cited in: NPJ Regen Med. 2024 Apr 29;9(1):17. [Abstract]

CCL3 was found to be the most altered cytokine by inhibiting G9a using BIX-01294 (1 μM). Inhibition of G9a using BIX-01294 (1 μM) largely altered the secretion in the F-EPC and OVX-EPC. ELISA showed secretory upregulation of CCL3 and VEGF-A in M-EPC, F-EPC, and OVX-EPC with the inhibition of G9a using BIX-01294.
Biomolecules

Targeting G9a Exerts Pleiotropic Suppression in Triple-Negative Breast Cancer Cells: Cooperatively Inducing Pyroptosis and Apoptosis. [Abstract]

2026 Feb 25;16(3):345. PMID: 41897283
Molecules

Modulatory Effect of Curcumin on Expression of Methyltransferase/Demethylase in Colon Cancer Cells: Impact on wt p53, mutp53 and c-Myc. [Abstract]

2025 Jul 22;30(15):3054. PMID: 40807229
Mol Med Rep

G9a inhibition promotes the formation of pacemaker-like cells by reducing the enrichment of H3K9me2 in the HCN4 promoter region. [Abstract]

2023 Feb;27(2):21. PMID: 36484369
Mol Med Rep

H3K9me2 regulates early transcription factors to promote mesenchymal stem‑cell differentiation into cardiomyocytes. [Abstract]

2021 Aug;24(2):616. PMID: 34184085
J Cell Mol Med

Larotrectinib induces autophagic cell death through AMPK/mTOR signalling in colon cancer. [Abstract]

2022 Nov;26(21):5539-5550. PMID: 36251949
iScience

miR-1307 promotes hepatocarcinogenesis by CALR-OSTC-endoplasmic reticulum protein folding pathway. [Abstract]

2021 Oct 14;24(11):103271. PMID: 34761190
Biomedicines

Exosome-Mediated Differentiation of Mouse Embryonic Fibroblasts and Exocrine Cells into β-Like Cells and the Identification of Key miRNAs for Differentiation. [Abstract]

2020 Nov 9;8(11):485. PMID: 33182285
Biochim Biophys Acta

YAP promotes breast cancer metastasis by repressing growth differentiation factor-15. [Abstract]

2018 May;1864(5 Pt A):1744-1753. PMID: 29499325
Exp Cell Res

Lamin B2 promotes the malignant phenotype of non-small cell lung cancer cells by upregulating dimethylation of histone 3 lysine 9. [Abstract]

2020 Aug 15;393(2):112090. PMID: 32416090
Invest New Drugs

BIX-01294, a G9a inhibitor, suppresses cell proliferation by inhibiting autophagic flux in nasopharyngeal carcinoma cells. [Abstract]

2021 Jun;39(3):686-696. PMID: 33387131
PLoS One

DNA methylation cooperates with H3K9me2 at HCN4 promoter to regulate the differentiation of bone marrow mesenchymal stem cells into pacemaker-like cells. [Abstract]

2023 Aug 29;18(8):e0289510. PMID: 37643180
Biochem Biophys Res Commun

Inhibition of histone-lysine N-methyltransferase G9a exacerbates alcoholic steatohepatitis (ASH) in mice. [Abstract]

2025 Nov 29:794:153072. PMID: 41344213
Biochem Biophys Res Commun

Inhibition of histone methyltransferase G9a aggravates phenotypic severity of hepatic lipotoxicity in non-alcoholic steatohepatitis (NASH). [Abstract]

2025 Jan:743:151171. PMID: 39693938
Cell J

High Expression of G9a Induces Cisplatin Resistance in Hepatocellular Carcinoma. [Abstract]

2023 Feb 1;25(2):118-125. PMID: 36840458
bioRxiv

A host-directed adjuvant resuscitates and sensitizes intracellular bacterial persisters to antibiotics. [Abstract]

2024 Oct 30:2024.09.30.615828. PMID: 39554024
Research Square Print

September 20th, 2022.
Aging (Albany NY)

Uhrf1 regulates H3K9me2 modification of mTOR to inhibit the effect of autophagy in myocardial ischemia-reperfusion injury. [Abstract]

2021 Mar 19;13(7):9704-9718. PMID: 33744855
bioRxiv

2020 Jun.
Patent

US20180263995A1.

Solvente y solubilidad

In Vitro:

DMSO : ≥ 110 mg/mL (224.20 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0382 mL

10.1908 mL

20.3815 mL

5 mM

0.4076 mL

2.0382 mL

4.0763 mL

10 mM

0.2038 mL

1.0191 mL

2.0382 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.75 mg/mL (5.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.75 mg/mL (5.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.75 mg/mL (5.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Nathaniel W Mabe, et al. G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program. Cell Rep. 2020 Nov 3;33(5):108341. [Content Brief]

[2]. Kubicek S, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007 Feb 9;25(3):473-81. [Content Brief]

[3]. Yang Q, et al. BIX-01294 treatment blocks cell proliferation, migration and contractility in ovine foetal pulmonary arterial smooth muscle cells. Cell Prolif. 2012 Aug;45(4):335-44. [Content Brief]

[4]. Iwona Anna Ciechomska, et al. BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells. Sci Rep [Content Brief]

[5]. Yanqi Chang, et al.Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol. 2009 Mar;16(3):312-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0382 mL	10.1908 mL	20.3815 mL	50.9539 mL
	5 mM	0.4076 mL	2.0382 mL	4.0763 mL	10.1908 mL
	10 mM	0.2038 mL	1.0191 mL	2.0382 mL	5.0954 mL
	15 mM	0.1359 mL	0.6794 mL	1.3588 mL	3.3969 mL
	20 mM	0.1019 mL	0.5095 mL	1.0191 mL	2.5477 mL
	25 mM	0.0815 mL	0.4076 mL	0.8153 mL	2.0382 mL
	30 mM	0.0679 mL	0.3397 mL	0.6794 mL	1.6985 mL
	40 mM	0.0510 mL	0.2548 mL	0.5095 mL	1.2738 mL
	50 mM	0.0408 mL	0.2038 mL	0.4076 mL	1.0191 mL
	60 mM	0.0340 mL	0.1698 mL	0.3397 mL	0.8492 mL
	80 mM	0.0255 mL	0.1274 mL	0.2548 mL	0.6369 mL
	100 mM	0.0204 mL	0.1019 mL	0.2038 mL	0.5095 mL

Keywords

BIX-01294

27 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

BIX-01294

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Reprogramming Compound Library

Anti-Blood Cancer Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) BIX-01294

Ver todos los productos específicos de isoformas Histone Methyltransferase

Actividad biológica

Chemical Information

Publications (27)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

BIX-01294

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Reprogramming Compound Library

Anti-Blood Cancer Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) BIX-01294

Ver todos los productos específicos de isoformas Histone Methyltransferase

Actividad biológica

Chemical Information

Publications (27)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

BIX-01294 Related Classifications

HY-10587 Related Classifications